logo
ENTITY

Silence Therapeutics (SLN LN)

9
Analysis
Health Care • United Kingdom
Silence Therapeutics plc, a RNA technology company, engages in the development and delivery of RNA therapeutics. The company has an intellectual property portfolio, encompassing proprietary and in-licensed patents and patent applications, covering various aspects of its RNA based therapeutics. Its patented RNA interference (RNAi) platform, AtuRNAi, is based on specific proprietary short interfering RNA (siRNA) modules, stabilization technology, and other features. The company also has proprietary lipid based RNA delivery technology platforms that comprise AtuPLEX, a lipid based siRNA formulation that delivers RNAi to the vascular endothelium; DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung; and HepaPLEX formulation that delivers siRNA primarily to the liver. It is developing Atu027, an RNAi drug candidate that has completed a Phase IIa study in pancreatic cancer. The company?s pre-clinical programs include Atu111 for the treatment of lung diseases; Messenger RNA (mRNA) delivery, a method of introducing messenger RNA activity into the cell, in conditions where this is of therapeutic interest; and MicroRNA delivery that mediate natural cellular mechanisms, which exist to regulate gene expression. It is also developing GalNAc conjugated siRNA for liver delivery and products for pulmonary arterial hypertension. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
more
bullish•Silence Therapeutics
•16 Apr 2020 18:12•Issuer-paid

Silence Therapeutics - A year of unprecedented change

The year 2019 marked a major turnaround for Silence, as it both ramped up its development activity, with the advancement of SLN124 for iron...

Logo
Share
bullish•Silence Therapeutics
•25 Mar 2020 22:05•Issuer-paid

Silence Therapeutics - Another major deal, this time with AstraZeneca

Silence Therapeutics announced on 25 March 2020 that it has signed a collaboration agreement with AstraZeneca to develop novel drugs for...

Logo
Share
bullish•Silence Therapeutics
•09 Jan 2020 16:36•Issuer-paid

Silence Therapeutics - Solving disease by targeting genes with siRNA

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a...

Logo
Share
bullish•Silence Therapeutics
•11 Apr 2017 21:42•Issuer-paid

Termination of coverage

Edison Investment Research is terminating coverage on Silence Therapeutics (SLN). Please note you should no longer rely on any previous research or...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x